Compare HOWL & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOWL | MATH |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.7M | 49.9M |
| IPO Year | 2021 | 2016 |
| Metric | HOWL | MATH |
|---|---|---|
| Price | $1.08 | $0.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 393.5K | 48.2K |
| Earning Date | 11-13-2026 | 08-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.73 |
| 52 Week High | $1.27 | $3.19 |
| Indicator | HOWL | MATH |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 46.68 |
| Support Level | $0.88 | $0.91 |
| Resistance Level | $1.12 | $1.16 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 80.00 | 35.57 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.